Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions

被引:0
|
作者
Slatter, JG [1 ]
Su, P [1 ]
Sams, JP [1 ]
Schaaf, LJ [1 ]
Wienkers, LC [1 ]
机构
[1] PHARMACIA & UPJOHN CO,CLIN PHARMACEUT,KALAMAZOO,MI 49007
关键词
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Human hepatic microsomes were used to investigate the carboxylesterase-mediated bioactivation of CPT-11 to the active metabolite, SN-38, SN-38 formation velocity was determined by HPLC over a concentration range of 0.25-200 mu M CPT-11. Biphasic Eadie Hofstee plots were observed in seven donors, suggesting that two isoforms catalyzed the reaction. Analysis by nonlinear least squares regression gave K-M estimates of 129-164 mu M with a V-max of 5.3-17 pmol/mg/min for the low affinity isoform. The high affinity isoform had K-M estimates of 1.4-3.9 mu M with V-max of 1.2-26 pmol/mg/min. The low K-M carboxylesterase may be the main contributor to SN-38 formation at clinically relevant hepatic concentrations of CPT-11. Using standard incubation conditions, the effects of potential inhibitors of carboxylesterase-mediated CPT-11 hydrolysis were evaluated at concentrations greater than or equal to 21 mu M. Positive controls bis-nitrophenylphosphate (BNPP) and physostigmine decreased CPT-11 hydrolysis to 1.3-3.3% and 23% of control values, respectively. Caffeine, acetylsalicylic acid, coumarin, cisplatin, ethanol, dexamethasone, 5-fluorouracil, loperamide, and prochlorperazine had no statistically significant effect on CPT-11 hydrolysis. Small decreases were observed with metoclopramide (91% of control), acetaminophen (93% of control), probenecid (87% of control), and fluoride (91% of control). Of the compounds tested above, based on these in vitro data, only the potent inhibitors of carboxylesterase (BNPP, physostigmine) have the potential to inhibit CPT-11 bioactivation if administered concurrently. The carboxylesterase-mediated hydrolysis of alpha-naphthyl acetate (alpha-NA) was used to determine whether CPT-11 was an inhibitor of hydrolysis of high turnover substrates of carboxylesterases. Inhibition of alpha-NA hydrolysis by CPT-11 was determined relative to positive controls BNPP and NaF. Incubation with microsomes pretreated with CPT-11 (80-440 mu M) decreased alpha-naphthol formation to approximately 80% of control at alpha-NA concentrations of 50-800 mu M. The inhibitors BNPP (360 mu M) and NaF (500 mu M) inhibited alpha-naphthol formation to 9-10% of control and to 14-20% of control, respectively. Therefore, CPT-11-sensitive carboxylesterase isoforms may account for only 20% of total alpha-NA hydrolases. Thus, CPT-11 is unlikely to significantly inhibit high turnover, nonselective substrates of carboxylesterases.
引用
收藏
页码:1157 / 1164
页数:8
相关论文
共 35 条
  • [21] Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase
    Rivory, LP
    Bowles, MR
    Robert, J
    Pond, SM
    BIOCHEMICAL PHARMACOLOGY, 1996, 52 (07) : 1103 - 1111
  • [22] Development and validation of an UPLC-MS/MS method for the determination of irinotecan (CPT-11), SN-38 and SN-38 glucuronide in human plasma and peritoneal tumor tissue from patients with peritoneal carcinomatosis
    Gasthuys, Elke
    van Ovost, Judith
    Vande Casteele, Sofie
    Cosyns, Sarah
    Ceelen, Wim
    Van Bocxlaer, Jan
    Vermeulen, An
    JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2024, 1233
  • [23] The transformation of irinotecan (CPT-11) to its active metabolite SN-38 by human liver microsomes - Differential hydrolysis for the lactone and carboxylate forms
    Haaz, MC
    Rivory, LP
    Riche, C
    Robert, J
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1997, 356 (02) : 257 - 262
  • [24] HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC DETERMINATION OF IRINOTECAN (CPT-11) AND ITS ACTIVE METABOLITE (SN-38) IN HUMAN PLASMA
    SUMIYOSHI, H
    FUJIWARA, Y
    OHUNE, T
    YAMAOKA, N
    TAMURA, K
    YAMAKIDO, M
    JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS, 1995, 670 (02): : 309 - 316
  • [25] SN-38, a metabolite of the camptothecin derivative CPT-11, potentiates the cytotoxic effect of radiation in human colon adenocarcinoma cells grown as spheroids
    Omura, M
    Torigoe, S
    Kubota, N
    RADIOTHERAPY AND ONCOLOGY, 1997, 43 (02) : 197 - 201
  • [26] Blocking of PI3K/Akt pathway enhances apoptosis induced by SN-38, an active form of CPT-11, in human hepatoma cells
    Koizumi, N
    Hatano, E
    Nitta, T
    Tada, M
    Harada, N
    Taura, K
    Ikai, I
    Shimahara, Y
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2005, 26 (05) : 1301 - 1306
  • [27] Sensitive determination of irinotecan (CPT-11) and its active metabolite SN-38 in human serum using liquid chromatography-electrospray mass spectrometry
    Ragot, S
    Marquet, P
    Lachâtre, F
    Rousseau, A
    Lacassie, E
    Gaulier, JM
    Dupuy, JL
    Lachâtre, G
    JOURNAL OF CHROMATOGRAPHY B, 1999, 736 (1-2): : 175 - 184
  • [28] Interaction of irinotecan (CPT-11) and its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) with human cytochrome P450 enzymes
    Hanioka, N
    Ozawa, S
    Jinno, H
    Tanaka-Kagawa, T
    Nishimura, T
    Ando, M
    Sawada, JI
    DRUG METABOLISM AND DISPOSITION, 2002, 30 (04) : 391 - 396
  • [29] Metabolism of irinotecan (CPT-11) by human hepatic microsomes:: Participation of cytochrome P-450 3A and drug interactions
    Haaz, MC
    Rivory, L
    Riché, C
    Vernillet, L
    Robert, J
    CANCER RESEARCH, 1998, 58 (03) : 468 - 472
  • [30] The transformation of irinotecan (CPT-11) to its active metabolite SN-38 by human liver microsomes Differential hydrolysis for the lactone and carboxylate formsDifferential hydrolysis for the lactone and carboxylate forms
    Marie-Christine Haaz
    L. P. Rivory
    Christian Riché
    J. Robert
    Naunyn-Schmiedeberg's Archives of Pharmacology, 1997, 356 : 257 - 262